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Subjects and methods
DNA was extracted from peripheral blood leucocytes from 276 white Caucasian subjects with newly diagnosed Type II diabetes included in the United Kingdom Prospective Diabetes Study (UKPDS) [9] , 351 subjects without diabetes from the Diabetes in Families study (DIF), randomly chosen from general practitioner lists, but unrelated to the probands. Approval of our ethical committee was obtained, and all individuals gave their informed consent for DNA analyses.
A subset of UKPDS subjects were chosen at random [9] from patients who either had a family history of diabetes and FPG of 8.0 mmol/l or more (n = 59); or were 50 years of age or under at diagnosis with FPG between 6.0 and 7.8 mmol/l (n = 25); or were 50 years of age or more at diagnosis with FPG between 6.0 and 15.0 mmol/l (n = 192).
UK Prospective Diabetes Study (UKPD subjects were GADA and ICA negative, 60 % male, age (mean (SD)) 51 [9] years, BMI 25.8 (5.3) kg m ±2 , fasting plasma glucose (median (IQR)) 7.8 (6.3 to 11.7) mmol/l, fasting plasma insulin (geometric mean (1SD interval)) 81(46 to 142) pmol/l, total cholesterol 5.3 (1.1) mmol/l, LDL-cholesterol 3.4 (1.0) mmol/l, HDLcholesterol 1.08 (0.22) mmol/l and plasma triglyceride (geometric mean (1SD interval)) 1.4 (0.9 to 2.2) mmol/l.
To assess islet dysfunction, UKPDS subjects were classified by requirement for insulin therapy 6 years after randomisation into the study. Subjects not randomised to insulin were deemed insulin-requiring when maximal doses of oral hypoglycaemic agents failed to maintain FPG at under 15.0 mmol/l. Those randomised to insulin therapy were deemed insulin requiring if their insulin dose was over 0.7 U/kg. In this situation requirement for insulin can be used as an indicator of islet dysfunction because endogenous insulin supply is insufficient to maintain glycaemia within acceptable levels.
Non-diabetic control subjects from DIF were 43 % male but of similar age (means SEM 55 (18) years) and BMI (25.3 (4.0) kg/m 2 ) to the UKPDS subjects. All gene variants were detected using fluorescently tagged primers and RFLPs which were identified against standards (Perkin Elmer, Foster City, Calif., USA) run on an automated sequencer (ABI 377, Applied Biosystems, Foster City, Calif., USA) except the ApoE 112 C-T which required RFLP analysis on agarose gels.
Statistical analyses were carried out with SAS statistical software package (SAS, Carey, N. C., USA). The significance of differences between genotypic and allelic frequency were assessed by chi square (c 2 ) or Fisher's exact test. Odds ratios (OR (95 %-CI)) were calculated from frequency tables. Comparisons of demographic and biochemical characteristics were done using Kruskal-Wallis and Mann-Whitney U tests or chi square (c 2 ) or Fisher's exact tests as appropriate. We considered a p value of less than 0.05 to be statistically significant.
Results
All genotypes examined were in Hardy-Weinberg equilibrium. An increased frequency (p = 0.00 079) of subjects homozygous for the BcHE K variant (AA) was observed in newly diagnosed Type II diabetic subjects (n = 276) compared with the non-diabetic control group (n = 348) ( Table 1 ). The frequency of the K-variant allele (A) was increased in the diabetic group compared with the control group (p = 0.00 017). The odds ratio (OR) of 1.44 (95 %-CI, 1.15 to 1.82) represents a 44 % increased risk of having diabetes associated with the presence of the K variant. There were no significant associations of genotypes or alleles with sex, age, BMI, FPG, plasma insulin, total, LDL-cholesterol or HDL-cholesterol fractions, or plasma triglyceride in these newly diagnosed Type II diabetic subjects. A similar distribution of genotype and allele frequencies was found in the DIF Type II diabetic subjects.
To determine whether there was an association with islet dysfunction, genotype and allele, frequencies were compared in relation to insulin requirement at 6 years after entry into the UKPDS (Table 1) . There were no significant differences in either genotype (p = 0.296) or allele (p = 0.121) frequencies between the insulin requiring (n = 50) and non-insulin requiring (n = 225) groups. These data indicate that although there is an association of the BcHE K variant with Type II diabetes, it is not related to islet dys-function as defined by the requirement for insulin therapy.
There was no association with diabetes of the genotype and allele frequencies for the a 2 M ins/deletion polymorphism ( Table 2) . Neither was there any association of the a 2 M variant with any of the demographic or biochemical characteristics of the UKPDS subjects. The allele frequencies were similar to those occurring in the general population.
The frequencies of ApoE polymorphisms in UKPDS diabetic subjects (Table 2) were similar to those in the normal population as reported previously [10] . The allele and genotype frequency distribution of the ApoE ±491 and ±219 promoter variants also reflected those in the general population [11] and no significant association was found for either variant with Type II diabetes. There were no significant associations of ±491 or ±219 promoter genotypes with any of the demographic or biochemical characteristics of the UKPDS subjects.
In control subjects, there were significant differences in both total and LDL-cholesterol concentrations in relation to the ApoE ±491 promoter genotypes. Total cholesterol concentration (means SEM was 4.7 (0.8) mmol/L (TT, n = 7) compared with 5.1 (1.) mmol/l (AT, n = 104) and 5.5 (1.1) mmol/l (AA, n = 236) (p = 0.0005). LDL-cholesterol concentration was 2.8 (0.7) mmol/l (TT) compared with 3.0 (0.8) mmol/l (AT) and 3.5 (1.0) mmol/l (AA) (p = 0.0009). Tests for trend across the genotypes did not reach statistical significance. There were no significant differences in HDL-cholesterol or plasma triglyceride concentrations in these groups.
Discussion
These data indicate an association between the variant for BcHE (encoded on chromosome 3q26) and diabetes. Diabetes susceptibility loci have been identified in 3q27-qter close to BcHE and quantitative trait loci for diabetes-related complications have also been reported in this region [3, 5] , suggesting that the K variant could be in linkage disequilibrium with an unidentified gene or genes. However this association is not related to the requirement for insulin treatment as might be expected if it were an important factor in islet dysfunction and amyloid deposition. No associations of ApoE common polymorphisms or the promoter variants with Type II diabetes were detected suggesting that activity of this gene does not play a primary role in causing hyperglycaemia.
